DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on June 4, 2008; DOI: 10.1124/dmd.108.020776


0090-9556/08/3609-1938-1943$20.00
DMD 36:1938-1943, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.020776v1
36/9/1938    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kotsuma, M.
Right arrow Articles by Tokui, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotsuma, M.
Right arrow Articles by Tokui, T.

Novel Binding Mode of the Acidic CYP2D6 Substrates Pactimibe and Its Metabolite R-125528

Masakatsu Kotsuma, Hiroyuki Hanzawa, Yoriko Iwata, Kenji Takahashi, and Taro Tokui

Drug Metabolism and Pharmacokinetics Research Laboratories (M.K., T.T.) and Advanced Technology Research Laboratories (H.H., Y.I.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; and Research Laboratories, Kyoto Pharmaceutical Industries, Ltd., Kyoto, Japan (K.T.)

Typical CYP2D6 substrates generally contain a basic nitrogen atom that interacts with Asp301 and/or Glu216 and an aromatic moiety adjacent to the site of metabolism. Recently, we found novel acidic substrates for CYP2D6, pactimibe, and its indole metabolite, R-125528, that are not protonated but are negatively charged at physiological pH. The Km value of R-125528 in CYP2D6-expressing microsomes was determined to be 1.74 µM, which was comparable with those of typical basic CYP2D6 substrates (1–10 µM). Pactimibe has lower affinity than R-125528; however, the Km value was comparable with that of metoprolol. Interestingly, their sites of metabolism, the {omega}-1 position of the N-octyl indoline/indole group, were relatively distant from the aromatic moiety. A pactimibe analog with an N-decyl chain was similarly labile against CYP2D6; however, analogs with N-hexyl or N-dodecyl chains were stable to CYP2D6. An induced fit docking of the ligands with an X-ray crystal structure of substrate-free CYP2D6 (Protein Data Bank code 2F9Q) indicated the involvement of an electrostatic interaction between the carboxyl group and Arg221 and hydrophobic interaction between the aromatic moiety and Phe483. The docking model correctly positioned the site of metabolism above the heme. The effect of the N-alkyl chain length of pactimibe analogs on their CYP2D6 metabolic stability was plausibly explained by the docking model. In conclusion, we report herein a novel CYP2D6 binding mode for the acidic substrates pactimibe and R-125528. Further investigation, such as a site-directed mutation, will be necessary to directly demonstrate the involvement of Arg221 in CYP2D6 binding.


Address correspondence to: Dr. Masakatsu Kotsuma, Daiichi Sankyo Co., LTD, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. E-mail: kotsuma.masakatsu.gu{at}daiichisankyo.co.jp







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.